Cargando…
P1176: RITUXIMAB IN PRIMARY CNS LYMPHOMA – LONG TERM FOLLOW-UP OF THE PHASE III HOVON 105/ALLG NHL 24 STUDY
| Autores principales: | , , , , , , , , , , , , , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Lippincott Williams & Wilkins
2022
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9429217/ http://dx.doi.org/10.1097/01.HS9.0000847568.17124.58 |
| _version_ | 1784779370615799808 |
|---|---|
| author | Doorduijn, J. Issa, S. van der Holt, B. Minnema, M. Seute, T. Durian, M. Cull, G. van der Poel, M. Stevens, W. Zijlstra, J. Nijland, M. Mason, K. Beeker, A. Brandsma, D. van den Bent, M. Gonzalez, M. de Jong, D. Bromberg, J. |
| author_facet | Doorduijn, J. Issa, S. van der Holt, B. Minnema, M. Seute, T. Durian, M. Cull, G. van der Poel, M. Stevens, W. Zijlstra, J. Nijland, M. Mason, K. Beeker, A. Brandsma, D. van den Bent, M. Gonzalez, M. de Jong, D. Bromberg, J. |
| author_sort | Doorduijn, J. |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-9429217 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2022 |
| publisher | Lippincott Williams & Wilkins |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-94292172022-08-31 P1176: RITUXIMAB IN PRIMARY CNS LYMPHOMA – LONG TERM FOLLOW-UP OF THE PHASE III HOVON 105/ALLG NHL 24 STUDY Doorduijn, J. Issa, S. van der Holt, B. Minnema, M. Seute, T. Durian, M. Cull, G. van der Poel, M. Stevens, W. Zijlstra, J. Nijland, M. Mason, K. Beeker, A. Brandsma, D. van den Bent, M. Gonzalez, M. de Jong, D. Bromberg, J. Hemasphere Posters Lippincott Williams & Wilkins 2022-06-23 /pmc/articles/PMC9429217/ http://dx.doi.org/10.1097/01.HS9.0000847568.17124.58 Text en Copyright © 2022 The Author(s). Published by Wolters Kluwer Health, Inc. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access Abstract Book distributed under the Attribution-NonCommercial-NoDerivs (CC BY-NC-ND) (https://creativecommons.org/licenses/by-nc-nd/4.0/) which allows third parties to download the articles and share them with others as long as they credit the author and the Abstract Book, but they cannot change the content in any way or use them commercially. |
| spellingShingle | Posters Doorduijn, J. Issa, S. van der Holt, B. Minnema, M. Seute, T. Durian, M. Cull, G. van der Poel, M. Stevens, W. Zijlstra, J. Nijland, M. Mason, K. Beeker, A. Brandsma, D. van den Bent, M. Gonzalez, M. de Jong, D. Bromberg, J. P1176: RITUXIMAB IN PRIMARY CNS LYMPHOMA – LONG TERM FOLLOW-UP OF THE PHASE III HOVON 105/ALLG NHL 24 STUDY |
| title | P1176: RITUXIMAB IN PRIMARY CNS LYMPHOMA – LONG TERM FOLLOW-UP OF THE PHASE III HOVON 105/ALLG NHL 24 STUDY |
| title_full | P1176: RITUXIMAB IN PRIMARY CNS LYMPHOMA – LONG TERM FOLLOW-UP OF THE PHASE III HOVON 105/ALLG NHL 24 STUDY |
| title_fullStr | P1176: RITUXIMAB IN PRIMARY CNS LYMPHOMA – LONG TERM FOLLOW-UP OF THE PHASE III HOVON 105/ALLG NHL 24 STUDY |
| title_full_unstemmed | P1176: RITUXIMAB IN PRIMARY CNS LYMPHOMA – LONG TERM FOLLOW-UP OF THE PHASE III HOVON 105/ALLG NHL 24 STUDY |
| title_short | P1176: RITUXIMAB IN PRIMARY CNS LYMPHOMA – LONG TERM FOLLOW-UP OF THE PHASE III HOVON 105/ALLG NHL 24 STUDY |
| title_sort | p1176: rituximab in primary cns lymphoma – long term follow-up of the phase iii hovon 105/allg nhl 24 study |
| topic | Posters |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9429217/ http://dx.doi.org/10.1097/01.HS9.0000847568.17124.58 |
| work_keys_str_mv | AT doorduijnj p1176rituximabinprimarycnslymphomalongtermfollowupofthephaseiiihovon105allgnhl24study AT issas p1176rituximabinprimarycnslymphomalongtermfollowupofthephaseiiihovon105allgnhl24study AT vanderholtb p1176rituximabinprimarycnslymphomalongtermfollowupofthephaseiiihovon105allgnhl24study AT minnemam p1176rituximabinprimarycnslymphomalongtermfollowupofthephaseiiihovon105allgnhl24study AT seutet p1176rituximabinprimarycnslymphomalongtermfollowupofthephaseiiihovon105allgnhl24study AT durianm p1176rituximabinprimarycnslymphomalongtermfollowupofthephaseiiihovon105allgnhl24study AT cullg p1176rituximabinprimarycnslymphomalongtermfollowupofthephaseiiihovon105allgnhl24study AT vanderpoelm p1176rituximabinprimarycnslymphomalongtermfollowupofthephaseiiihovon105allgnhl24study AT stevensw p1176rituximabinprimarycnslymphomalongtermfollowupofthephaseiiihovon105allgnhl24study AT zijlstraj p1176rituximabinprimarycnslymphomalongtermfollowupofthephaseiiihovon105allgnhl24study AT nijlandm p1176rituximabinprimarycnslymphomalongtermfollowupofthephaseiiihovon105allgnhl24study AT masonk p1176rituximabinprimarycnslymphomalongtermfollowupofthephaseiiihovon105allgnhl24study AT beekera p1176rituximabinprimarycnslymphomalongtermfollowupofthephaseiiihovon105allgnhl24study AT brandsmad p1176rituximabinprimarycnslymphomalongtermfollowupofthephaseiiihovon105allgnhl24study AT vandenbentm p1176rituximabinprimarycnslymphomalongtermfollowupofthephaseiiihovon105allgnhl24study AT gonzalezm p1176rituximabinprimarycnslymphomalongtermfollowupofthephaseiiihovon105allgnhl24study AT dejongd p1176rituximabinprimarycnslymphomalongtermfollowupofthephaseiiihovon105allgnhl24study AT brombergj p1176rituximabinprimarycnslymphomalongtermfollowupofthephaseiiihovon105allgnhl24study |